50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,643.03 (-2.04%)
DOW   29,244.72 (-1.48%)
QQQ   271.86 (-2.89%)
AAPL   143.51 (-4.22%)
MSFT   236.01 (-2.10%)
META   137.36 (-3.00%)
GOOGL   96.80 (-3.25%)
AMZN   114.72 (-2.79%)
TSLA   271.92 (-5.52%)
NVDA   121.91 (-4.28%)
NIO   15.69 (-9.46%)
BABA   78.30 (-3.32%)
AMD   64.32 (-5.91%)
T   15.56 (-1.71%)
MU   50.01 (-1.94%)
CGC   2.85 (-6.25%)
F   11.58 (-4.93%)
GE   62.63 (-2.84%)
DIS   97.65 (-1.76%)
AMC   7.26 (-5.35%)
PYPL   89.58 (-1.69%)
PFE   44.25 (-0.41%)
NFLX   242.24 (-1.21%)
S&P 500   3,643.03 (-2.04%)
DOW   29,244.72 (-1.48%)
QQQ   271.86 (-2.89%)
AAPL   143.51 (-4.22%)
MSFT   236.01 (-2.10%)
META   137.36 (-3.00%)
GOOGL   96.80 (-3.25%)
AMZN   114.72 (-2.79%)
TSLA   271.92 (-5.52%)
NVDA   121.91 (-4.28%)
NIO   15.69 (-9.46%)
BABA   78.30 (-3.32%)
AMD   64.32 (-5.91%)
T   15.56 (-1.71%)
MU   50.01 (-1.94%)
CGC   2.85 (-6.25%)
F   11.58 (-4.93%)
GE   62.63 (-2.84%)
DIS   97.65 (-1.76%)
AMC   7.26 (-5.35%)
PYPL   89.58 (-1.69%)
PFE   44.25 (-0.41%)
NFLX   242.24 (-1.21%)
S&P 500   3,643.03 (-2.04%)
DOW   29,244.72 (-1.48%)
QQQ   271.86 (-2.89%)
AAPL   143.51 (-4.22%)
MSFT   236.01 (-2.10%)
META   137.36 (-3.00%)
GOOGL   96.80 (-3.25%)
AMZN   114.72 (-2.79%)
TSLA   271.92 (-5.52%)
NVDA   121.91 (-4.28%)
NIO   15.69 (-9.46%)
BABA   78.30 (-3.32%)
AMD   64.32 (-5.91%)
T   15.56 (-1.71%)
MU   50.01 (-1.94%)
CGC   2.85 (-6.25%)
F   11.58 (-4.93%)
GE   62.63 (-2.84%)
DIS   97.65 (-1.76%)
AMC   7.26 (-5.35%)
PYPL   89.58 (-1.69%)
PFE   44.25 (-0.41%)
NFLX   242.24 (-1.21%)
S&P 500   3,643.03 (-2.04%)
DOW   29,244.72 (-1.48%)
QQQ   271.86 (-2.89%)
AAPL   143.51 (-4.22%)
MSFT   236.01 (-2.10%)
META   137.36 (-3.00%)
GOOGL   96.80 (-3.25%)
AMZN   114.72 (-2.79%)
TSLA   271.92 (-5.52%)
NVDA   121.91 (-4.28%)
NIO   15.69 (-9.46%)
BABA   78.30 (-3.32%)
AMD   64.32 (-5.91%)
T   15.56 (-1.71%)
MU   50.01 (-1.94%)
CGC   2.85 (-6.25%)
F   11.58 (-4.93%)
GE   62.63 (-2.84%)
DIS   97.65 (-1.76%)
AMC   7.26 (-5.35%)
PYPL   89.58 (-1.69%)
PFE   44.25 (-0.41%)
NFLX   242.24 (-1.21%)
CVE:HEM

Hemostemix - HEM Stock Forecast, Price & News

C$0.16
0.00 (0.00%)
(As of 09/29/2022 10:25 AM ET)
Add
Compare
Today's Range
C$0.16
C$0.16
50-Day Range
C$0.16
C$0.37
52-Week Range
C$0.13
C$0.42
Volume
17,676 shs
Average Volume
104,634 shs
Market Capitalization
C$12.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$0.96
HEM stock logo

About Hemostemix (CVE:HEM) Stock

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

Receive HEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter.

HEM Stock News Headlines

Hemostemix Announces A Clarification
Hemostemix Announces Unit Private Placement
Hemostemix, Leucrotta Lone Stocks at 52-Week Highs
Hemostemix Announces Settlement Agreement
Hemostemix Announces $2,750,000 Convertible Debenture
Hemostemix Announces Stock Options Grant
See More Headlines
Receive HEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$0.96
High Stock Price Forecast
C$0.96
Low Stock Price Forecast
C$0.96
Forecasted Upside/Downside
+500.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.01 per share
Book Value
C($0.07) per share

Miscellaneous

Free Float
N/A
Market Cap
C$12.12 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Thomas A. Smeenk B.A. (Age 60)
    BA Hons, Co-Founder, Pres, CEO & Director
    Comp: $223.74k
  • Ms. Christina Wu CPA
    Interim Chief Financial Officer
  • Dr. Fraser C. Henderson Sr.
    M.D., Interim Chief Medical Officer













HEM Stock - Frequently Asked Questions

Should I buy or sell Hemostemix stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hemostemix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HEM shares.
View HEM analyst ratings
or view top-rated stocks.

What is Hemostemix's stock price forecast for 2022?

1 equities research analysts have issued twelve-month price targets for Hemostemix's shares. Their HEM share price forecasts range from C$0.96 to C$0.96. On average, they predict the company's share price to reach C$0.96 in the next year. This suggests a possible upside of 500.0% from the stock's current price.
View analysts price targets for HEM
or view top-rated stocks among Wall Street analysts.

How have HEM shares performed in 2022?

Hemostemix's stock was trading at C$0.16 at the beginning of 2022. Since then, HEM stock has increased by 0.0% and is now trading at C$0.16.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Hemostemix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), Gene Biotherapeutics (CRXM), Camber Energy (CEI), Auxly Cannabis Group (CBWTF), Cannabis Science (CBIS), Beazer Homes USA (BZH), Big Tree Group (BIGG), Asterias Biotherapeutics (AST) and

What is Hemostemix's stock symbol?

Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM."

How do I buy shares of Hemostemix?

Shares of HEM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Hemostemix's stock price today?

One share of HEM stock can currently be purchased for approximately C$0.16.

How much money does Hemostemix make?

Hemostemix (CVE:HEM) has a market capitalization of C$12.12 million.

How can I contact Hemostemix?

Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The official website for the company is www.hemostemix.com. The biotechnology company can be reached via phone at +1-403-3409207.

This page (CVE:HEM) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.